Torna ai risultati
Scheda bibliografica · Consultazione e accesso
Artículo

Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method

Varsha Thorat et al · SpringerOpen · 2026

Materiale supplementare disponibile
Lettura rapida. Controlla i dati essenziali della risorsa e accedi al contenuto con il pulsante principale. La scheda mostra solo le informazioni necessarie per identificare, citare e aprire l’opera.

Accesso alla risorsa

Apri il contenuto dall’opzione principale o scegli un’altra fonte disponibile.

DOAJ DOAJ Articles
Entrar por DOAJ
Accesso principale

Materiale supplementare disponibile

El enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Apri materiale

Riepilogo

Descripción general del contenido del recurso.

Abstract Background A sustainable and stability-indicating reversed-phase high-pressure liquid chromatography (RP-HPLC) method has been developed for the simultaneous estimation of chlorthalidone (CHL), Amlodipine (AML), and olmesartan medoxomil (OLM) in a combined cardiovascular dosage form by implementing an Analytical Quality by Design (AQbD) approach. Methods The RP-HPLC system employed a Sunniest C18 column (150 mm × 4.6 mm, 5.0 μm). The mobile phase consisted of 0.1% triethylamine in water (pH 2.4) and ethanol in a ratio of (65:35 v/v). At a flow rate of 1.5 mL/min. Detection was carried out at 245 nm using a photodiode array detector. Method optimization was performed using a Central composite design (CCD) under the AQbD framework. Forced degradation studies were conducted under acid, base, oxidative, thermal, and photolytic conditions to assess the method’s stability-indicating capability. Results The method showed good linearity in the 50–150% of test concentration with correlation coefficients (r2) exceeding 0.99 for all analytes. The method precision was found 98.9% for CHL and 101.4% for both AML and OLM. Forced degradation studies confirmed the method’s ability to resolve the active pharmaceutical ingredients from their degradation products. Well-separated, spectrally pure peaks were obtained for all analytes under all stress conditions, as confirmed by peak purity values greater than 0.950, indicating no interference from degradation products. The method demonstrated accuracy, precision, specificity, robustness as per the International Conference on Harmonization guidelines. Environmental sustainability was evaluated with GAPI (77), AMGS123, AGREEprep (0.69), and AGREE (0.81) scores, confirming its eco-friendly nature. Conclusions The integrated approach reduced solvent consumption, waste generation, and energy usage, supporting sustainable analysis. The method, validated as per ICH Q2(R2) guidelines, exhibited excellent linearity, precision, accuracy, specificity, robustness, and ruggedness. Forced degradation studies confirmed its stability-indicating capability. The present study highlights the need for incorporating antioxidants and implementing precautions against acidic and alkaline degradation, along with adopting proper packaging and storage strategies to enhance the stability of CHL, OLM, and AML in formulations prone to degradation.. Graphical abstract

Come citare

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, V. T. E. (2026). Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method. https://doi.org/10.1186/s43094-026-00985-w

MLA

al, Varsha Thorat et. "Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method." 2026. https://doi.org/10.1186/s43094-026-00985-w.

Chicago

al, Varsha Thorat et. 2026. "Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method.". https://doi.org/10.1186/s43094-026-00985-w.

Harvard

al, V. T. E. 2026, Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method, SpringerOpen, available at: https://doi.org/10.1186/s43094-026-00985-w [Accessed 7 Aug. 2026].

Condividi e stampa

Salva la scheda, copia il link permanente o stampala in PDF.

Esporta riferimento

Esporta il record nei formati più comuni per usarlo con un gestore bibliografico.

Dettagli della risorsa

Informazioni bibliografiche utili per verificare che sia il materiale corretto.

Titolo
Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method
Autore / collaboratori
Varsha Thorat et al
Editore
SpringerOpen
Anno di pubblicazione
2026
ISSN
2314-7253
ISSN
2314-7253
Lingua
Inglés

Soggetti

Esplora risorse correlate a partire da questi soggetti.

Copiato